Integration of pharmacotherapy and bariatric surgery in the treatment of obesity: Advances and challenges
- 15 May 2025
- journal article
- Published by Elsevier in Cirugía Española (English Edition)
- Vol. 103 (6) , 800116
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular DiseaseCanadian Journal of Cardiology, 2025
- Changes in Adult Obesity Trends in the USJAMA Health Forum, 2024
- International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)British Journal of Surgery, 2024
- Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysisObesity Surgery, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Obesity Management in AdultsJAMA, 2023
- Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic SurgeryJAMA Surgery, 2023
- Contemporary medical, device, and surgical therapies for obesity in adultsThe Lancet, 2023
- Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control StudyObesity Surgery, 2020
- Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysisExpert Review of Pharmacoeconomics & Outcomes Research, 2017